NASDAQ:IOSPInnospec Stock Price, Forecast & News

Innospec's stock was trading at $72.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IOSP shares have increased by 6.4% and is now trading at $77.09. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innospec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innospec.

Innospec is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Innospec.

Innospec Inc. (NASDAQ:IOSP) posted its quarterly earnings data on Tuesday, May, 5th. The specialty chemicals company reported $1.42 EPS for the quarter. The specialty chemicals company had revenue of $372.30 million for the quarter, compared to the consensus estimate of $380 million. Innospec had a net margin of 7.79% and a return on equity of 14.77%. The company's revenue was down 4.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.25 earnings per share. View Innospec's earnings history.

Innospec announced a semi-annual dividend on Thursday, May 7th. Shareholders of record on Monday, May 18th will be paid a dividend of $0.52 per share on Tuesday, May 26th. This represents a yield of 1.5%. The ex-dividend date is Friday, May 15th. View Innospec's dividend history.

1 Wall Street analysts have issued 12 month price objectives for Innospec's shares. Their forecasts range from $95.00 to $95.00. On average, they expect Innospec's share price to reach $95.00 in the next year. This suggests a possible upside of 23.2% from the stock's current price. View analysts' price targets for Innospec.

News headlines about IOSP stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Innospec earned a news impact score of 2.0 on InfoTrie's scale. They also gave press coverage about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutInnospec.

Innospec saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 367,900 shares, a decline of 12.5% from the April 30th total of 420,300 shares. Based on an average daily trading volume, of 135,600 shares, the short-interest ratio is presently 2.7 days. Currently, 1.5% of the company's stock are short sold. View Innospec's Current Options Chain.

Some companies that are related to Innospec include Ecolab (ECL), Sherwin-Williams (SHW), International Flavors & Fragrances (IFF), Celanese (CE), RPM International (RPM), Albemarle (ALB), NewMarket (NEU), Ashland Global (ASH), W. R. Grace & Co (GRA), Balchem (BCPC), Quaker Chemical (KWR), PolyOne (POL), Stepan (SCL), Sensient Technologies (SXT) and HB Fuller (FUL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Innospec investors own include Altria Group (MO), NVIDIA (NVDA), Sherwin-Williams (SHW), Applied Materials (AMAT), Activision Blizzard (ATVI), Broadcom (AVGO), Boeing (BA), Caterpillar (CAT), Colgate-Palmolive (CL) and Clorox (CLX).

Innospec trades on the NASDAQ under the ticker symbol "IOSP."

Innospec's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (14.89%), Wells Fargo & Company MN (6.00%), State Street Corp (3.08%), Champlain Investment Partners LLC (2.78%), Janus Henderson Group PLC (2.18%) and Geode Capital Management LLC (1.56%). Company insiders that own Innospec stock include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Ian Malcolm Mcrobbie, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View institutional ownership trends for Innospec.

IOSP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wasatch Advisors Inc., Kirr Marbach & Co. LLC IN, Nuveen Asset Management LLC, Morgan Stanley, Morgan Stanley, Hillsdale Investment Management Inc., and Thrivent Financial for Lutherans. Company insiders that have sold Innospec company stock in the last year include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Philip Curran, and Philip John Boon. View insider buying and selling activity for Innospec.

IOSP stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Invesco Ltd., State Street Corp, Geode Capital Management LLC, Champlain Investment Partners LLC, Canada Pension Plan Investment Board, Trexquant Investment LP, and Eagle Asset Management Inc.. View insider buying and selling activity for Innospec.

Shares of IOSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IOSP stock can currently be purchased for approximately $77.09.

Innospec has a market capitalization of $1.89 billion and generates $1.51 billion in revenue each year. Innospec employs 2,000 workers across the globe.

The official website for Innospec is www.innospecinc.com.

Innospec's mailing address is 8310 SOUTH VALLEY HIGHWAY SUITE 350, ENGLEWOOD CO, 80112. The specialty chemicals company can be reached via phone at 303-792-5554 or via email at [email protected]